Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension

Last updated: July 16, 2014
Sponsor: Alcon Research
Overall Status: Completed

Phase

3

Condition

Vascular Diseases

Stress

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT00928590
C-09-032
EudraCT Number 2009-013178-42
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to describe the long-term safety of a fixed combination product containing an alternative preservative, dosed once daily for 12 months, in patients with open-angle glaucoma or ocular hypertension.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Willing and able to sign an informed consent document.

  • Open-angle glaucoma or ocular hypertension who would benefit from a fixed combinationmedication, in the opinion of the investigator.

  • Stable treatment of an IOP-lowering medication.

  • Other protocol-defined inclusion criteria may apply.

Exclusion

Exclusion Criteria:

  • Pregnant, breastfeeding, or not using adequate birth control.

  • Best-corrected visual acuity (BCVA) worse than 55 ETDRS letters.

  • Other protocol-defined exclusion criteria may apply.

Study Design

Total Participants: 155
Study Start date:
July 01, 2009
Estimated Completion Date:
November 30, 2010

Connect with a study center

  • Contact Alcon Call Center For Trial Locations

    Fort Worth, Texas 76134
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.